Physician Search
Consuelo Wilkins, MD, MSCI, Senior Vice President for Health Equity and Inclusive Excellence for Vanderbilt University Medical Center (VUMC) and Senior Associate Dean for Health Equity and Inclusive Excellence for Vanderbilt University School of Medicine, always knew she wanted to be a physician. "Health equity was built into everything I did, even if I didn’t know it or recognize it at the time," Wilkins said. "I have always learned and believed that people are the same — everyone deserves to be healthy, and everyone should have the best opportunities to take care of themselves and their families." Click below to learn more about health equity initiatives. https://momentum.vicc.org/2021/09/everyone-deserves-to-be-healthy/ |
Vanderbilt was the lead site for an NIH-funded, phase 2, multicenter influenza vaccine study in pediatric allogeneic hematopoietic stem cell transplant (HCT) recipients that may lead to a change in the current flu vaccine recommendations in this vulnerable population. Natasha Halasa, MD, MPH and colleagues recently published in the New England Journal of Medicine, that two doses of high-dose trivalent flu vaccine resulted in higher amounts of influenza-specific antibodies than two doses of standard dose quadrivalent vaccine. https://news.vumc.org/2023/03/02/high-dose-flu-vaccine-beneficial-for-pediatric-stem-cell-transplant-patients/ |
A Combined Biomarker Model for Risk Stratification of Indeterminate Pulmonary Nodules - A Multicenter Prospective Observational Pilot Study
Lung
Lung
This study is being done to evaluate a combined biomarker model for risk stratification of indeterminate pulmonary nodules.
Lung
N/A
Grogan, Eric
NCT06074133
VICC-EDTHO23230
Molecular Predictors of Lung Cancer Behavior. (SPORE)
Multiple Cancer Types
Lung,
Non Small Cell,
Small Cell
N/A
Maldonado, Fabien
NCT00898313
VICCTHO0398
Molecular Fingerprinting of Lung Cancer (SPORE)
Multiple Cancer Types
Lung,
Non Small Cell
N/A
Grogan, Eric
NCT00897117
VICCTHO0136
Using Biomarkers and Imaging in Fungal Regions to Improve Lung Cancer Diagnosis
Lung
Lung
Lung
N/A
Grogan, Eric
VICCTHO1764
Nashville Biosciences Blood Sample Collection Study
Multiple Cancer Types
Colon,
Liver,
Lung,
Non Small Cell,
Ovarian,
Pancreatic,
Rectal
N/A
Bernard, Gordon
VICCMD18123
Cancer Patient Safety Learning Laboratory (CaPSLL): Preventing Clinical Deterioration in Outpatients
Multiple Cancer Types
Head/Neck,
Lung
N/A
Weinger, Matthew
VICCMD1998
Validating an Integrated Biomarker and Imaging Approach in the Evaluation of Indeterminate Pulmonary Nodules.
Lung
Lung
Lung
N/A
Grogan, Eric
VICCTHO2002
Non-Chemotherapy Treatment (Ramucirumab plus Pembrolizumab) or Standard Chemotherapy for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Trial
Lung
Lung
This phase III trial compares the effect of the combination therapy with ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if combination therapy with ramucirumab and pembrolizumab could help patients with stage IV or recurrent non-small cell lung cancer live longer compared to standard chemotherapy.
Lung
III
Iams, Wade
NCT05633602
VICC-NTTHO23073